ECSP11011384A - Sales de adición de trometamina con derivados de ácido azabifenilaminobenzoico como inhibidores de dhodh. - Google Patents

Sales de adición de trometamina con derivados de ácido azabifenilaminobenzoico como inhibidores de dhodh.

Info

Publication number
ECSP11011384A
ECSP11011384A EC2011011384A ECSP11011384A ECSP11011384A EC SP11011384 A ECSP11011384 A EC SP11011384A EC 2011011384 A EC2011011384 A EC 2011011384A EC SP11011384 A ECSP11011384 A EC SP11011384A EC SP11011384 A ECSP11011384 A EC SP11011384A
Authority
EC
Ecuador
Prior art keywords
addition salts
azabifenylaminobenzoic
trometamine
acid derivatives
dhodh inhibitors
Prior art date
Application number
EC2011011384A
Other languages
English (en)
Inventor
Gonzalez Nuria Garcia
Masia Xavier Serra
Carrera Francese Carrera
Jane Montserrat Julia
Laurent Debethune
Original Assignee
Gonzalez Nuria Garcia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40671396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011384(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gonzalez Nuria Garcia filed Critical Gonzalez Nuria Garcia
Publication of ECSP11011384A publication Critical patent/ECSP11011384A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a nuevas sales de adición cristalinas de (i) trometamina con (ii) un derivado de ácido azabifenilaminobenzoico de fórmula (I) en la queR1 se selecciona del grupo que consiste en alquilo C1-C4, cicloalquilo C3-C4 y CF3, G1 se selecciona de átomos de nitrógeno y grupos CH, C(CH3) y C(CF3), y G2 representa un grupo fenilo opcionalmente sustituido con uno o dos sustituyentes seleccionados de cloro, fluoro, metoxi, etoxi, isopropoxi, trifluorometoxi, CF3, y CONR7R8, en donde R7 es hidrógeno y R8 es ciclopropilo o R7 y R8 junto con el átomo de nitrógeno al que están unidos forman un grupo de fórmuladonde n es 1.y sus solvatos farmacéuticamente aceptables.
EC2011011384A 2009-03-13 2011-10-07 Sales de adición de trometamina con derivados de ácido azabifenilaminobenzoico como inhibidores de dhodh. ECSP11011384A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09382032A EP2230232A1 (en) 2009-03-13 2009-03-13 Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors

Publications (1)

Publication Number Publication Date
ECSP11011384A true ECSP11011384A (es) 2011-11-30

Family

ID=40671396

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011384A ECSP11011384A (es) 2009-03-13 2011-10-07 Sales de adición de trometamina con derivados de ácido azabifenilaminobenzoico como inhibidores de dhodh.

Country Status (21)

Country Link
US (1) US20120003183A1 (es)
EP (2) EP2230232A1 (es)
JP (1) JP2012520251A (es)
KR (1) KR20110126695A (es)
CN (1) CN102341372A (es)
AR (1) AR075737A1 (es)
AU (1) AU2010223527A1 (es)
CA (1) CA2754785A1 (es)
CL (1) CL2011002213A1 (es)
CO (1) CO6501157A2 (es)
EA (1) EA201101298A1 (es)
EC (1) ECSP11011384A (es)
IL (1) IL214517A0 (es)
MX (1) MX2011009147A (es)
NZ (1) NZ594491A (es)
PE (1) PE20120328A1 (es)
SG (2) SG173824A1 (es)
TW (1) TW201033177A (es)
UY (1) UY32465A (es)
WO (1) WO2010102825A1 (es)
ZA (1) ZA201105743B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) * 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
CA3060390A1 (en) 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
CA3091792A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
CN110903219A (zh) * 2018-09-18 2020-03-24 广东东阳光药业有限公司 酰胺衍生物的盐及其制备方法
BR112021012305A2 (pt) 2018-12-21 2021-10-05 Les Laboratoires Servier Sas Formas cristalinas e salinas de um composto orgânico e composições farmacêuticas das mesmas
WO2025227007A1 (en) * 2024-04-26 2025-10-30 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9804343D0 (en) 1998-02-27 1998-04-22 Univ Cardiff Chemical compounds
DK1381356T3 (da) 2001-04-05 2008-09-22 Aventis Pharma Inc Anvendelse af (z)-z-cyano-3-hydroxy-but-2-enoinsyre-(4-trifluoromethylphenyl) - amide til behandling af multipel sclerose
PE20030120A1 (es) * 2001-06-19 2003-02-12 Merck & Co Inc Sal amina de un antagonista de receptor de integrin
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
WO2004056747A1 (en) 2002-12-23 2004-07-08 4Sc Ag Dhodh-inhibitors and method for their identification
WO2004056746A1 (en) 2002-12-23 2004-07-08 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
AU2005257862A1 (en) 2004-05-21 2006-01-05 The Uab Research Foundation Compositions and methods relating to pyrimidine synthesis inhibitors
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
SG142305A1 (en) 2004-10-19 2008-05-28 Aventis Pharma Inc Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'- trifluoromethylphenyl)-amide for treating inflammatory bowel disease
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico

Also Published As

Publication number Publication date
EP2406222A1 (en) 2012-01-18
CL2011002213A1 (es) 2012-03-09
NZ594491A (en) 2013-11-29
WO2010102825A1 (en) 2010-09-16
EA201101298A1 (ru) 2012-04-30
MX2011009147A (es) 2011-09-15
US20120003183A1 (en) 2012-01-05
IL214517A0 (en) 2011-09-27
AU2010223527A1 (en) 2011-08-25
ZA201105743B (en) 2012-04-25
SG173824A1 (en) 2011-09-29
EP2230232A1 (en) 2010-09-22
KR20110126695A (ko) 2011-11-23
PE20120328A1 (es) 2012-03-29
CO6501157A2 (es) 2012-08-15
UY32465A (es) 2010-05-31
CA2754785A1 (en) 2010-09-16
CN102341372A (zh) 2012-02-01
AR075737A1 (es) 2011-04-20
JP2012520251A (ja) 2012-09-06
SG10201400568PA (en) 2014-07-30
TW201033177A (en) 2010-09-16

Similar Documents

Publication Publication Date Title
UY32465A (es) Sales de adicion de trometamina con derivados de acido azabifenilaminobenzoico como inhibidores de dhodh
ECSP10010337A (es) Derivados de carboxamidas azabicíclicas, su preparación y su aplicación en terapéutica
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
AR066107A1 (es) Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica como inhibidores de la enzimamonoacil glicerol lipasa y composiciones qu los contienen.
AR082112A1 (es) Derivados de imidazopiridina, su procedimiento de preparacion y su aplicacion en terapeutica
AR081426A1 (es) Derivados de pirazol inhibidores del receptor sigma
ECSP11011365A (es) Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh
ECSP10010359A (es) Derivados bicíclicos de carboxamidas aza-bicíclicas, su preparación y su aplicación terapéutica
ECSP12012212A (es) Derivados de ariletinilo
UY39338A (es) Derivados de piperidinona como inhibidores mdm2, composiciones farmacéuticas que los contienen y sus usos
CO6290677A2 (es) Procesos e intermediarios para la preparación de derivados de acido 5-bifenil-4-il-2-metilpentanoico.
UY33226A (es) Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
AR082768A1 (es) Derivados de indolizina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen
AR083903A1 (es) Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos
AR072803A1 (es) Tetrahidrocinolinas como inhibidores de la 11- beta -hsd1 para la diabetes
CO6150150A2 (es) Derivados de 7-alquinil-1,8-naftiridonas su prepacion y su aplicacion en terapeutica
AR090557A1 (es) DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
CU20100157A7 (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112013017416A2 (pt) derivado de indola ou indazola ou sal do mesmo
CR20130476A (es) Derivados de pirazolidin-3-ona
UY32246A (es) Derivados de carbamatos de alquil-heterociclos, su preparación y su aplicación en terapéutica
ES2572052T3 (es) Amidas macrocíclicas como inhibidores de proteasas
ES2570659T3 (es) Agonistas de adenosina A1 para el tratamiento del glaucoma y de la hipertensión ocular
AR082973A1 (es) Derivados de dihidrobenzoxatiazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR074514A1 (es) Derivados de morfina-6-glucuronido, su preparacion y su aplicacion en terapeutica